Home ›
Lung Cancer Trials ›
NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Trial Details
NCT ID NCT07128199
Phase PHASE3
Sponsor Taiho Oncology, Inc.
Status RECRUITING
Cancer Type Lung Cancer
Interventions TAS6417 Zipalertinib Matching-placebo
Locations (sample) Anchorage, Alaska, United States|61.21806,-149.90028 Duarte, California, United States|34.13945,-117.97729 Irvine, California, United States|33.66946,-117.82311 La Jolla, California, United States|32.84727,-117.2742 Vallejo, California, United States|38.10409,-122.25664
Key Eligibility Criteria
Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[… exon20 insertion mutations (ex20ins) or other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) exons 18-21 of the EGFR tyrosine kinase domain
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →